CS
ALDR

Candriam SCA’s Alder Biopharmaceuticals ALDR Stock Holding History

Candriam SCA’s Portfolio ALDR Stock Details ALDR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-227,500
Closed -$2.67M – 839
2019
Q2 		$2.67M Hold
227,500
– – 0.03% 452
2019
Q1 		$3.11M Hold
227,500
– – 0.04% 410
2018
Q4 		$2.33M Hold
227,500
– – 0.04% 425
2018
Q3 		$3.79M Buy
227,500
+10,000
+5% +$181K 0.05% 377
2018
Q2 		$3.44M Buy
217,500
+41,500
+24% +$631K 0.05% 369
2018
Q1 		$2.23M Buy
176,000
+75,000
+74% +$1.08M 0.04% 457
2017
Q4 		$1.16M Sell
101,000
-16,000
-14% -$179K 0.02% 566
2017
Q3 		$1.43M Hold
117,000
– – 0.03% 510
2017
Q2 		$1.34M Buy
117,000
+8,000
+7% +$148K 0.03% 534
2017
Q1 		$2.27M Buy
109,000
+69,000
+173% +$1.53M 0.04% 419
2016
Q4 		$832K Hold
40,000
– – 0.02% 544
2016
Q3 		$1.31M Buy
+40,000
New +$1.22M 0.03% 444
2015
Q3 		– Sell
-40,000
Closed -$2.12M – 657
2015
Q2 		$2.12M Buy
+40,000
New +$1.45M 0.04% 356

Other funds holding ALDR

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $494M AUM 23.45% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Candriam SCA's ALDR Position: Q3 2019 in Review

Candriam SCA sold out of Alder Biopharmaceuticals (ALDR) in Q3 2019, closing a stake of 227,500 shares — an estimated $2.67M sold.

Candriam SCA first reported a position in ALDR in Q2 2015 and held it in 13 quarters. The position peaked at $3.79M in Q3 2018. 143 funds tracked by Wall St. Rank hold ALDR as of Q3 2019.

  • Candriam SCA reported no remaining Alder Biopharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Candriam SCA sold 227,500 Alder Biopharmaceuticals shares in Q3 2019, an estimated $2.67M.
  • Candriam SCA first reported a position in Alder Biopharmaceuticals in Q2 2015 and held it in 13 quarters.
  • Candriam SCA's Alder Biopharmaceuticals position peaked at $3.79M in Q3 2018.
  • 143 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q3 2019.

Based on Candriam SCA's 13F filing for Q3 2019, filed 21 Oct 2019.